PMID- 20817125
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20220309
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Print)
IS  - 1549-9634 (Linking)
VI  - 7
IP  - 2
DP  - 2011 Apr
TI  - Curcumin nanodisks: formulation and characterization.
PG  - 162-7
LID - 10.1016/j.nano.2010.08.002 [doi]
AB  - Nanodisks (NDs) are nanoscale, disk-shaped phospholipid bilayers whose edge is 
      stabilized by apolipoproteins. In the present study, NDs were formulated with the 
      bioactive polyphenol curcumin at a 6:1 phospholipid-to-curcumin molar ratio. 
      Atomic force microscopy revealed that curcumin-NDs are particles with diameters 
      <50 nm and the thickness of a phospholipid bilayer. When formulated in NDs, 
      curcumin is water soluble and gives rise to a characteristic absorbance spectrum 
      with a peak centered at 420 nm. Fluorescence spectroscopy of curcumin-NDs 
      provided evidence of self-quenching. Incubation of curcumin-NDs with empty NDs 
      relieved the self-quenching, indicating redistribution of curcumin between 
      curcumin-loaded and empty NDs. In HepG2 cells, curcumin-NDs mediated enhanced 
      cell growth inhibition as compared with free curcumin. In a cell culture model of 
      mantle cell lymphoma, curcumin-NDs were a more potent inducer of apoptosis than 
      free curcumin. The nanoscale size of the complexes, combined with their ability 
      to solubilize curcumin, indicates NDs may have in vivo therapeutic applications. 
      FROM THE CLINICAL EDITOR: Nanodisks (NDs), disk-shaped phospholipid bilayers 
      stabilized by apolipoproteins, are shown entrap curcumin and improve its delivery 
      to HepG2 and mantle cell lymphoma cells in culture. These novel nanocomplexes 
      demonstrate interesting therapeutic application potentials.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Ghosh, Mistuni
AU  - Ghosh M
AD  - Department of Nutritional Sciences and Toxicology, University of California 
      Berkeley, Berkeley, California, USA.
FAU - Singh, Amareshwar T K
AU  - Singh AT
FAU - Xu, Wenwei
AU  - Xu W
FAU - Sulchek, Todd
AU  - Sulchek T
FAU - Gordon, Leo I
AU  - Gordon LI
FAU - Ryan, Robert O
AU  - Ryan RO
LA  - eng
GR  - R37 HL064159/HL/NHLBI NIH HHS/United States
GR  - R43 CA141904-01/CA/NCI NIH HHS/United States
GR  - HL64159/HL/NHLBI NIH HHS/United States
GR  - 1R43CA141904/CA/NCI NIH HHS/United States
GR  - R43 CA141904/CA/NCI NIH HHS/United States
GR  - R01 HL064159-11/HL/NHLBI NIH HHS/United States
GR  - R01 HL064159/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20101001
PL  - United States
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Drug Carriers)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Anti-Inflammatory Agents/administration & dosage/chemistry/pharmacology
MH  - Antineoplastic Agents/*administration & dosage/chemistry/pharmacology
MH  - Antioxidants/administration & dosage/chemistry/pharmacology
MH  - Cell Proliferation/drug effects
MH  - Chemistry, Pharmaceutical
MH  - Curcumin/*administration & dosage/chemistry/pharmacology
MH  - Drug Carriers/*chemistry/pharmacology
MH  - Hep G2 Cells
MH  - Humans
MH  - Nanostructures/*chemistry
PMC - PMC3030927
MID - NIHMS234032
COIS- Conflicts of Interest: The authors declare no competing financial interests
EDAT- 2010/09/08 06:00
MHDA- 2011/07/23 06:00
PMCR- 2012/04/01
CRDT- 2010/09/07 06:00
PHST- 2010/05/10 00:00 [received]
PHST- 2010/07/25 00:00 [revised]
PHST- 2010/08/11 00:00 [accepted]
PHST- 2010/09/07 06:00 [entrez]
PHST- 2010/09/08 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - S1549-9634(10)00245-5 [pii]
AID - 10.1016/j.nano.2010.08.002 [doi]
PST - ppublish
SO  - Nanomedicine. 2011 Apr;7(2):162-7. doi: 10.1016/j.nano.2010.08.002. Epub 2010 Oct 
      1.